1. Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, et al. Global cancer observatory: cancer today. Lyon (France): International Agency for Research on Cancer; 2018. https://gco.iarc.fr/today [accessed Sep 8, 2020].
2. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidlines®). Ovarian cancer including fallopian tube cancer and primary peritoneal cancer (version 1.2020); 2020. https://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf [accessed Sep 8, 2020].
3. ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease;Colombo;Ann Oncol,2019
4. The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy;Hanker;Ann Oncol,2012
5. Ovarian Cancer Research Alliance. Recurrence and treatment for ovarian cancer recurrence; 2019. https://ocrahope.org/patients/about-ovarian-cancer/recurrence/ [accessed Sep 8, 2020].